Motif Bio is a clinical stage biopharmaceutical company developing novel antibiotics to treat patients with serious and life-threatening infections caused by multi-drug resistant bacteria.
|Motif Bio Announces Resignation of Robert Bertoldi from Board of Directors|
July 3, 2018
|Result of Annual General Meeting|
June 19, 2018
|Motif Bio Submits NDA for Iclaprim|
June 14, 2018